single20MG
Ovagen
20MG Protocol
Ovagen 20MG
Injection Freq.
Inject once daily
Cycle Sched.
Daily subcutaneous injections for 16 weeks with gradual titration
Reconstitution
2.0 mL BAC water
Bioregulator concept for gastrointestinal/hepatic tissue signaling (preclinical framework)
In vitro cytoprotective signals via modulation of aging-related gene expression
Ultrashort peptides described as low-immunogenic and rapidly metabolized
HIV-1 protease inhibition binding described in biochemical studies
1
Reconstitution Requirements
- 2.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 10 μg (0.01 mg) | 0.1 |
| 2 | Weeks 3–4 | 20 μg (0.02 mg) | 0.2 |
| 3 | Weeks 5–6 | 50 μg (0.05 mg) | 0.5 |
| 4 | Weeks 7–8 | 100 μg (0.1 mg) | 1 |
| 5 | Weeks 9–16 | 100–150 μg (0.1–0.15 mg) | 1.5 |
Inject once daily
Daily subcutaneous injections for 16 weeks with gradual titration
Ovagen (Glu–Asp–Leu; EDL) is described as an ultrashort tripeptide studied as a tissue bioregulator, with emphasis on gene-level regulation rather than classic receptor agonism. The protocol explains that ultrashort peptides are hypothesized to enter cells and interact with DNA, thereby influencing gene expression and protein synthesis. In vitro evidence cited on the page includes increased cell proliferation and changes in aging-related gene markers (such as p16, p21, p53, and SIRT-6) in renal cell cultures—findings framed as potentially cytoprotective. The protocol also notes that ultrashort peptides have been studied for effects on differentiation, proliferation, and apoptosis via gene regulation. An additional mechanistic note is EDL’s reported binding within the active site of HIV-1 protease, described as an inhibitory interaction in biochemical studies. The page stresses that controlled human trials are not available; therefore, any dosing approach is extrapolated from preclinical and cell-based findings.
Side-effect profile not well characterized (limited human data)
Mild injection-site reactions (redness/itching)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)